Bronchopulmonary Dysplasia (BPD)

01Pathophysiology

Understanding BPD requires distinguishing between two forms: the "old" (classic) BPD and the "new" BPD. This distinction is critical because exam vignettes now overwhelmingly reflect the new form.

Classic BPD was described by Northway in 1967 and occurred in relatively more mature preterm infants (30 to 34 weeks) exposed to high-pressure mechanical ventilation and high concentrations of inspired oxygen. The mechanism involved direct barotrauma and oxygen free radical injury to the developing airway epithelium and alveolar tissue. This triggered a cycle of inflammation, fibrosis, smooth muscle hypertrophy, and airway remodeling. Histologically, classic BPD showed alternating areas of emphysema and fibrosis with squamous metaplasia of the airways.

New BPD, the predominant form seen today, occurs in extremely premature infants (< 28 weeks) whose lungs are in the canalicular or early saccular stage of development. The introduction of antenatal steroids and exogenous surfactant has improved survival for these infants, but the lungs are exposed to extrauterine conditions long before alveolarization is complete. The hallmark is arrested alveolar development: instead of the normal 300 to 400 million alveoli, the lungs develop fewer, larger, and simplified alveolar structures with a decreased surface area for gas exchange. Simultaneously, pulmonary vascular growth is disrupted, with reduced capillary density and abnormal vascular remodeling. This vascular component is what drives the development of pulmonary hypertension, one of the most dangerous complications.

The connection between pathophysiology and clinical presentation is direct. Fewer alveoli with simplified architecture means a lower gas exchange surface area, leading to persistent oxygen dependence. Decreased pulmonary vascular bed increases pulmonary vascular resistance, creating a predisposition to cor pulmonale (right ventricular failure). The compliance of the lung is reduced, so the infant must generate greater negative intrathoracic pressure to ventilate, causing the visible retractions and tachypnea that define the clinical picture.

Several prenatal and postnatal factors amplify this process. Chorioamnionitis triggers a fetal inflammatory response that primes the lung for further injury. A hemodynamically significant PDA increases pulmonary blood flow, contributing to pulmonary edema and worsening ventilator dependence. Postnatal sepsis activates systemic inflammation that further disrupts alveolar septation. All of these factors converge on a final common pathway: inflammation-driven arrest of normal lung maturation.

02Classification and Clinical Manifestation

Severity Classification (2001 NHLBI/NICHD Consensus)

The diagnosis of BPD requires that the infant has received supplemental oxygen for at least 28 cumulative days. Severity is then assessed at the following time points:

Clinical Manifestation by System

03Diagnostic Workup

BPD is fundamentally a clinical diagnosis. There is no single confirmatory laboratory test or imaging study that establishes the diagnosis. Instead, the diagnosis is made when a premature infant meets the temporal criterion (oxygen use for at least 28 days) and is then stratified by severity at the appropriate assessment time point. This is the most tested concept.

Chest radiography is the best initial imaging study and should be obtained in any premature infant with ongoing respiratory symptoms. In the new form of BPD, expect to see diffuse haziness or fine granular opacities without the dramatic cystic changes that characterized classic BPD. Hyperinflation may or may not be present. The radiograph often looks deceptively mild compared to the clinical severity, a point that exam vignettes may exploit.

Arterial blood gas analysis typically reveals a compensated respiratory acidosis: $pC{O}_{2}pCO\_2$ is chronically elevated (often 50 to 65 mmHg), and the serum $HC{O}_3^{-}HCO\_3^-$ is elevated as renal compensation. This compensated state is tolerated and does not in itself necessitate escalation of ventilatory support, a concept known as permissive hypercapnia.

Echocardiography is essential and often under-tested by students. Pulmonary hypertension develops in a substantial proportion of infants with moderate-to-severe BPD and is one of the strongest predictors of mortality. An echocardiogram should be obtained in any infant with BPD who has persistent oxygen requirements, frequent desaturation events, or clinical signs of right heart failure. The finding of an elevated estimated RVSP via a tricuspid regurgitation jet velocity is the key result.

High-resolution CT is not part of the routine workup. It is reserved for infants with atypical clinical courses, disproportionate symptoms relative to CXR findings, or when an alternative structural diagnosis is suspected (e.g., congenital pulmonary airway malformation, pulmonary interstitial glycogenosis).

04Management and Treatment

Management Reasoning

Prevention is the highest-yield management concept for BPD on exams. The single most important preventive measure is antenatal corticosteroids, which accelerate fetal lung maturation by inducing surfactant production and thinning the alveolar-capillary membrane. This should be administered to all women at risk of preterm delivery between 23 and 34 weeks of gestation.

Caffeine citrate is the most commonly tested pharmacologic intervention for BPD prevention. The landmark CAP (Caffeine for Apnea of Prematurity) trial demonstrated that early caffeine administration reduces the incidence of BPD. The mechanism involves both respiratory stimulation (reducing apnea and the need for mechanical ventilation) and potential anti-inflammatory effects on the developing lung. Caffeine is started within the first 10 days of life in premature infants at risk for BPD.

For infants who develop established BPD and remain ventilator-dependent, diuretics are the first-line adjunctive therapy. Furosemide provides rapid relief of pulmonary edema but carries risks of electrolyte derangement (hypokalemia, hypochloremia, metabolic alkalosis), nephrocalcinosis, and ototoxicity with prolonged use. For chronic diuretic therapy, the combination of chlorothiazide and spironolactone is preferred because of a more favorable side-effect profile.

Systemic corticosteroids (dexamethasone) represent a double-edged sword and are among the most commonly tested management dilemmas. Dexamethasone accelerates extubation and reduces the duration of oxygen dependence, but it increases the risk of cerebral palsy and neurodevelopmental impairment when given in the first 7 days of life. Current guidelines recommend reserving systemic steroids for infants who remain ventilator-dependent beyond the first 1 to 2 weeks of life, using low-dose protocols, and only after a thorough discussion of risks with the family. The DART (Dexamethasone: A Randomized Trial) protocol starts at 0.15 mg/kg/day and tapers over 10 days.

Inhaled budesonide, sometimes instilled directly with surfactant as a vehicle, has emerged as an alternative strategy to reduce BPD incidence with potentially fewer systemic side effects. However, long-term neurodevelopmental safety data remain under investigation.

Nutritional support is critical. Infants with BPD have increased caloric expenditure from their elevated work of breathing. Caloric intake must be optimized to 120 to 150 kcal/kg/day, often requiring fortified breast milk or specialized high-calorie preterm formulas. Simultaneously, fluid intake is mildly restricted (130 to 150 mL/kg/day) to minimize pulmonary edema.

Palivizumab, a monoclonal antibody against RSV, is indicated for RSV prophylaxis during the RSV season. Infants with BPD are at extremely high risk for severe RSV bronchiolitis, and this prophylaxis significantly reduces hospitalization rates.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on BPD questions is by confusing the definition with the diagnosis of RDS. A vignette will describe a premature infant who had RDS at birth, received surfactant, and then "never got better" or "still requires supplemental oxygen weeks later." The trap is selecting RDS again or assuming a new acute process. The correct answer is BPD, and the key phrase is the persistent oxygen requirement at or beyond 28 days.

The second major trap involves systemic corticosteroids. Students frequently select dexamethasone as a management step without recognizing the timing restriction. Giving systemic steroids within the first 7 days of life increases the risk of cerebral palsy. If the vignette describes an infant in the first week of life who is ventilator-dependent, the correct answer is to continue supportive care, optimize ventilation, and administer caffeine. Systemic steroids become a reasonable option only in a persistently ventilator-dependent infant beyond 1 to 2 weeks of age.

A third trap is failing to screen for pulmonary hypertension. A vignette describing a BPD infant with worsening oxygenation, hepatomegaly, or right-sided heart failure cues should prompt the selection of echocardiography, not an escalation of diuretics or another chest X-ray.

Finally, remember that caffeine is a preventive agent, not a rescue therapy for established BPD. If the vignette asks about reducing the incidence of BPD in a newly born premature infant, caffeine citrate is the answer. If the question describes an infant who already has established BPD with pulmonary edema, the answer is diuretics, not caffeine.

The core competency being tested across BPD questions is the ability to recognize a chronic process evolving from an acute neonatal disease, to sequence preventive and therapeutic interventions correctly along the timeline, and to identify complications (particularly pulmonary hypertension) that change the management approach.